Executive Insights

The results of PwC’s 22nd annual survey of 1,300-plus CEOs, which were launched this week at the World Economic Forum Annual Meeting in Davos, Switzerland, shows that nearly 30% believe…

Drug pricing took center stage once again with a proposal by US Department of Health and Human Services Secretary Alex Azar to require drug companies in the US, for the…

A recent analysis by Deloitte of 400 CEOs and board members from US organizations with $1 billion or more in annual revenues examines executives views on four critical strategic risks,…

Pfizer announced that Ian Read, current Chairman and CEO of Pfizer will step down as CEO January 1, 2019 to be succeeded as CEO by Albert Bourla, the company’s current…

What has been the impact on business strategy as a result of US corporate tax reform, which was signed into law in December 2017? A recent PwC survey of US…

What are the key developments in pharmaceutical manufacturing? From large-scale biomanufacturing projects, to advances in cell and gene therapy production, and continuous manufacturing, DCAT Value Chain Insights looks at significant…

UK Prime Minister Theresa May faces external and internal hurdles and the possibility of a “no deal,” meaning the UK would leave the European Union (EU) without a Brexit agreement.…

Cambrex, a contract manufacture of small-molecule active pharmaceutical ingredients, is the latest contract manufacturer to establish an end-to-end-business model with its pending $425-million acquisition of Halo Pharmaceuticals, a CDMO of…

Pfizer announced last week that it will reorganize into three businesses, an Innovative Medicines business, an Established Medicines unit, and a Consumer Healthcare business. So what is the restructuring all…

So which mergers and acquisitions among pharmaceutical companies have made the mark thus far in 2018? DCAT Value Chain Insights takes an inside look. Two $60-billlion deals top the list.…